OJRA  Vol.3 No.4 , November 2013
Applying Item Response Theory Methods to Improve the Measurement of Fatigue in a Clinical Trial of Rheumatoid Arthritis Patients Treated with Secukinumab*
Abstract: Background: Many clinical trials include multiple patient-reported outcomes (PROs) to measure fatigue as secondary or exploratory endpoints of treatment effectiveness. Often, these instruments have overlapping content. The objective of this study was to compare the combined measurement properties of two fatigue scales, the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) and SF-36 vitality (VT) scale using item response theory (IRT). Methods: The FACIT-Fatigue and SF-36v2 were administered at baseline and weeks 2, 4, 7, 12, and 16 to rheumatoid arthritis (RA) patients (n = 237) enrolled in a 52-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose finding study to evaluate the efficacy and safety of subcutaneous secukinumab administered to pa- tients with active RA. Confirmatory factor analysis (CFA) was used to investigate unidimensionality among FACIT- Fatigue and VT items. A generalized partial credit IRT model was used to cross-calibrate the FACIT-Fatigue and VT items and weighted maximum-likelihood estimation was used to score a composite fatigue index. Analysis of variance was used to compare the composite fatigue index with the original scales in responding to ACR improvement and treatment effects. Results: CFA found less than adequate fit to a unidimensional model. However, specifications of alternative multidimensional models were insufficient in explaining the common variance among items. An IRT model was successfully fitted and the composite fatigue index score was found to be more responsive than the original scales to ACR improvement and treatment effects. Effect sizes and significance tests for changes in scores on the composite index were generally larger than those observed with the original scales. Conclusion: IRT methods offer a promising approach to combining items from different scales measuring the same concept that could improve the detection of treatment effects in clinical studies of RA.  
Cite this paper: M. Kosinski, J. Bjorner, A. Gnanasakthy, U. Mallya and S. Mpofu, "Applying Item Response Theory Methods to Improve the Measurement of Fatigue in a Clinical Trial of Rheumatoid Arthritis Patients Treated with Secukinumab*," Open Journal of Rheumatology and Autoimmune Diseases, Vol. 3 No. 4, 2013, pp. 192-201. doi: 10.4236/ojra.2013.34030.

[1]   D. Symmons, G. Turner, R. Webb, et al., “The Prevalence of Rheumatoid Arthritis in the United Kingdom: New Estimates for a New Century,” Rheumatology, Vol. 41, No. 7, 2002, pp. 793-800.

[2]   K. Jordan, A. M. Clarke, D. P. Symmons, D. Fleming, M. Porcheret, U. T. Kadam, et al., “Measuring Disease Prevalence: A Comparison of Musculoskeletal Disease Using Four General Practice Consultation Databases,” British Journal of General Practices, Vol. 57, No. 534, 2007, pp. 7-14.

[3]   L. A. Rodriguez, L. B. Tolosa, A. Ruigomez, S. Johansson and M. A. Wallander, “Rheumatoid Arthritis in UK Primary Care: Incidence and Prior Morbidity,” Scandinavia Journal of Rheumatology, Vol. 38, No. 3, 2009, pp. 173- 177.

[4]   M. M. Ward, H. S. Javitz and E. H. Yelin, “The Direct Cost of Rheumatoid Arthritis,” Value Health, Vol. 3, No. 4, 2000, pp. 243-252.

[5]   R. C. Kessler, J. R. Maclean, M. Petukhova, C. A. Sarawate, L. Short, T. T. Li, et al., “The Effects of Rheumatoid Arthritis on Labor Force Participation, Work Performance, and Healthcare Costs in Two Workplace Samples,” Journal of Occupational and Environmental Medicine, Vol. 50, No. 1, 2008, pp. 88-98.

[6]   R. J. Ozminkowski, W. N. Burton, R. Z. Goetzel, R. Maclean and S. Wang, “The Impact of Rheumatoid Arthritis on Medical Expenditures, Absenteeism, and Short-Term Disability Benefits,” Journal of Occupational and Environmental Medicine, Vol. 48, No. 2, 2006, pp. 135-148.

[7]   C. H. van Jaarsveld, J. W. Jacobs, A. J. Schrijvers, G. A. Albada-Kuipers, D. M. Hofman and J. W. Bijlsma, “Effects of Rheumatoid Arthritis on Employment and Social Participation during the First Years of Disease in The Netherlands,” British Journal of Rheumatology, Vol. 37, No. 8, 1998, pp. 848-853.

[8]   F. Wolfe, K. Michaud, H. K. Choi and R. Williams, “Household Income and Earnings Losses among 6396 Persons with Rheumatoid Arthritis,” Journal of Rheumatology, Vol. 32, No. 10, 2005, pp. 1875-1883.

[9]   M. Kosinski, S. C. Kujawski, R. Martin, L. A. Wanke, M. C. Buatti, J. E. Ware, et al., “Health-Related Quality of Life in Early Rheumatoid Arthritis: Impact of Disease and Treatment Response,” American Journal of Managed Care, Vol. 8, No. 3, 2002, pp. 231-240.

[10]   T. P. Suurmeijer, M. Waltz, T. Moum, F. Guillemin, F. L. van Sonderen, S. Briancon, et al., “Quality of Life Profiles in the First Years of Rheumatoid Arthritis: Results from the EURIDISS Longitudinal Study,” Arthritis Rheum, Vol. 45, No. 2, 2001, pp. 111-121.<111::AID-ANR162>3.0.CO;2-E

[11]   J. Talamo, A. Frater, S. Gallivan and A. Young, “Use of the Short Form 36 (SF36) for Health Status Measurement in Rheumatoid Arthritis,” British Journal of Rheumatology, Vol. 36, No. 4, 1997, pp. 463-469.

[12]   T. Sokka, B. Abelson and T. Pincus, “Mortality in Rheumatoid Arthritis: 2008 Update,” Clinical and Experimental Rheumatology, Vol. 26, No. 5, 2008, pp. S35-S61.

[13]   A. M. Wasserman, “Diagnosis and Management of Rheumatoid Arthritis,” American Family Physician, Vol. 84, No. 11, 2011, pp. 1245-1252.

[14]   K. G. Saag, G. G. Teng, N. M. Patkar, J. Anuntiyo, C. Finney, J. R. Curtis, et al., “American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis,” Arthritis Rheum, Vol. 59, No. 6, 2008, pp. 762-784.

[15]   R. B. Terry and G. Singh, “Quality of Life Measures in the Treatment of Arthritis in Clinical Practice,” New Standards in Arthiritis Care, Vol. 5, No. 3, 2013, pp. 2-6.

[16]   T. Pincus, R. H. Brooks and L. F. Callahan, “Prediction of Long Term Mortality in Patients with Rheumatoid Arthritis According to Simple Questionnaire and Joint Count Measures,” Annals of Internal Medicine, Vol. 120, No. 1, 1994, pp. 26-34.

[17]   D. Aletaha, R. Landewe, T. Karonitsch, J. Bathon, M. Boers, C. Bombardier, et al., “Reporting Disease Activity in Clinical Trials of Patients with Rheumatoid Arthritis: EULAR/ACR Collaborative Recommendations,” Annals of the Rheumatic Diseases, Vol. 67, No. 10, 2008, pp. 1360-1364.

[18]   J. E. Ware Jr. and C. D. Sherbourne, “The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual Framework and Item Selection,” Medical Care, Vol. 30, No. 6, 1992, pp. 473-483.

[19]   D. Cella, S. Yount, M. Sorensen, E. Chartash, N. Sengupta and J. Grober, “Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale Relative to Other Instrumentation in Patients with Rheumatoid Arthritis,” Journal of Rheumatology, Vol. 32, No. 5, 2005, pp. 811-819.

[20]   J. B. Bjorner, M. Kosinski, X. Sun and J. E. Ware Jr., “Calibration of Item Banks for Use in Improving Estimates of Eight SF-36 Health Constructs,” 2006.

[21]   J. B. Bjorner, M. Kosinski and J. E. Ware Jr., “Using Item Response Theory to Calibrate the Headache Impact Test (HIT) to the Metric of Traditional Headache Scales,” Quality Life Research, 2003, pp. 981-1002.

[22]   J. B. Bjorner, M. Kosinski and J. E. Ware Jr., “Calibration of an Item Pool for Assessing the Burden of Headaches: An Application of Item Response Theory to the Headache Impact Test (HITTM),” Quality of Life Research, Vol. 12, No. 8, 2003, pp. 887-902.

[23]   J. Fries, M. Rose and E. Krishnan, “The PROMIS of Better Outcome Assessment: Responsiveness, Floor and Ceiling Effects, and Internet Administration,” Journal of Rheumatology, Vol. 38, No. 8, 2011, pp. 1759-1764.

[24]   M. Rose, J. B. Bjorner, J. Becker, J. F. Fries and J. E. Ware, “Evaluation of a Preliminary Physical Function Item Bank Supported the Expected Advantages of the Patient-Reported Outcomes Measurement Information System (PROMIS),” Journal of Clinical Epidemiology, Vol. 61, No. 1, 2008, pp. 17-33.

[25]   J. B. Bjorner, M. Kosinski and J. E. Ware Jr., “The Feasibility of Applying Item Response Theory to Measures of Migraine Impact: A Reanalysis of Three Clinical Studies,” Quality Life Research, Vol. 12, No. 8, 2003, pp. 887-902.

[26]   M. Kosinski, J. B. Bjorner, J. E. Ware Jr., A. Batenhorst and R. K. Cady, “The Responsiveness of Headache Impact Scales Scored Using ‘Classical’ and ‘Modern’ Psychometric Methods: A Re-Analysis of Three Clinical Trials,” Quality Life Research, Vol. 12, No. 8, 2003, pp. 903-912.

[27]   M. Martin, M. Kosinski, J. B. Bjorner, J. E. Ware Jr., R. Maclean and T. Li, “Item Response Theory Methods Can Improve the Measurement of Physical Function by Combining the Modified Health Assessment Questionnaire and the SF-36 Physical Function Scale,” Quality Life Research, Vol. 16, No. 4, 2007, pp. 647-660.

[28]   M. Genovese, P. Durez, H. Richards, et al., “Secukinumab Improves Signs and Symptoms in Patients with Active Rheumatoid Arthritis: Results of Dose-Finding, Double-Blind, Randomized, Placebo-Controlled, Phase II Studies,” World Psoriasis & Psoriatic Arthritis Conference, 2012.

[29]   D. Cella, “The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: A New Tool for the Assessment of Outcomes in Cancer Anemia and Fatigue,” Seminars in Hematology, Vol. 34, No. 3, 1997, pp. 13-19.

[30]   D. F. Cella, D. S. Tulsky, G. Gray, B. Sarafian, E. Linn, A. Bonomi, et al., “The Functional Assessment of Cancer Therapy Scale: Development and Validation of the General Measure,” Journal of Clinical Oncology, Vol. 11, No. 3, 1993, pp. 570-579.

[31]   K. Webster, D. Cella and K. Yost, “The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: Properties, Applications, and Interpretation,” Health Quality Life Outcomes, Vol. 1, 2003, p. 79.

[32]   J. E. Ware Jr., K. K. Snow, M. Kosinski and B. Gandek, “SF-36 Health Survey Manual and Interpretation Guide,” The Health Institite, New England Medical Center, Boston, 1993.

[33]   J. E. Ware Jr., M. Kosinski and J. Dewey, “How to Score Version Two of the SF-36 Health Survey,” Quality Metric Inc., Lincoln, 2000.

[34]   “Mplus User’s Guide [Computer Program],” Version 1. Muthén & Muthén, Los Angeles, 1998.

[35]   P. M. Bentler, “Comparative Fit Indexes in Structural Models,” Psychological Bulletin, Vol. 107, No. 2, 1990, pp. 238-246.

[36]   L. Hu and P. M. Bentler, “Cutoff Criteria for Fit Indexes in Covariance Structure Analysis: Conventional Criteria versus New Alternatives,” Structural Equation Modeling, Vol. 6, No. 1, 1999, pp. 1-55.

[37]   M. W. Browne and R. Cudeck, “Alternative Ways of Assessing Model Fit,” Sociological Methods and Research, Vol. 21, No. 2, 1992, pp. 230-258.

[38]   R. P. McDonald, “Test Theory: A Unified Treatment,” Lawrence Erlbaum Associates, Hillsdale, 1999.

[39]   G. N. Mastersm, “A Rasch Model for Partial Credit Scoring,” Psychometrika, Vol. 47, No. 2, 1982, pp. 149-173.

[40]   F. Samejima, “Graded Response Model,” In: W. J. van der Linden and R. K. Hambleton, Eds., Handbook of Modern Item Response Theory, Springer, Berlin, 1997, pp. 85-100.

[41]   R. D. Bock and R. J. Mislevy, “Adaptive EAP Estimation of Ability in a Microcomputer Environment,” Applied Psychological Measurement, Vol. 6, No. 4, 1982, pp. 431-444.

[42]   C. A. McHorney, J. E. Ware Jr. and A. E. Raczek, “The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs,” Medical Care, Vol. 31, No. 3, 1993, pp. 247-263.

[43]   C. A. McHorney, S. M. Haley and J. E. Ware Jr., “Evaluation of the MOS SF-36 Physical Function Scale (PF-10): II. Comparison of Relative Precision Using Likert and Rasch Scoring Methods,” Journal of Clinical Epidemiology, Vol. 50, No. 4, 1997, pp. 451-461.

[44]   W. J. Taylor and K. M. McPherson, “Using Rasch Analysis to Compare the Psychometric Properties of the Short Form 36 Physical Function Score and the Health Assessment Questionnaire Disability Index in Patients with Psoriatic Arthritis and Rheumatoid Arthritis,” Arthritis Care & Research, Vol. 57, No. 5, 2007, pp. 723-729.